ArticleFrontiers in oncology2023

Case Report: Long-term complete response to PSMA-targeted radioligand therapy and abiraterone in a metastatic prostate cancer patient.

David Parker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.